S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
NASDAQ:AURA

Aura Biosciences Stock Forecast, Price & News

$17.75
-4.87 (-21.53%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.61
$22.20
50-Day Range
N/A
52-Week Range
$14.00
$26.16
Volume
189,556 shs
Average Volume
184,568 shs
Market Capitalization
$518.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive AURA News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Aura Biosciences logo

About Aura Biosciences

Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass.

Headlines

Aura Biosciences (NASDAQ:AURA) Shares Gap Down to $22.62
November 29, 2021 |  americanbankingnews.com
Aura Biosciences (NASDAQ:AURA) Trading Up 4.6%
November 26, 2021 |  americanbankingnews.com
Aura Biosciences’ Q3 Loss Widens
November 26, 2021 |  nasdaq.com
Aura Biosciences (NASDAQ:AURA) Shares Gap Up to $17.95
November 24, 2021 |  americanbankingnews.com
SVB Leerink Initiates Coverage on Aura Biosciences (NASDAQ:AURA)
November 23, 2021 |  americanbankingnews.com
Aura Biosciences (NASDAQ:AURA) Shares Down 13.3%
November 23, 2021 |  americanbankingnews.com
BTIG Research Begins Coverage on Aura Biosciences (NASDAQ:AURA)
November 23, 2021 |  americanbankingnews.com
Aura Biosciences (NASDAQ:AURA) Now Covered by Evercore ISI
November 23, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AURA
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$518.48 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

782nd out of 1,392 stocks

Biological Products, Except Diagnostic Industry

117th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Aura Biosciences (NASDAQ:AURA) Frequently Asked Questions

Is Aura Biosciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aura Biosciences stock.
View analyst ratings for Aura Biosciences
or view top-rated stocks.

What price target have analysts set for AURA?

4 brokerages have issued 12 month price objectives for Aura Biosciences' stock. Their forecasts range from $35.00 to $40.00. On average, they anticipate Aura Biosciences' stock price to reach $37.67 in the next year. This suggests a possible upside of 112.2% from the stock's current price.
View analysts' price targets for Aura Biosciences
or view top-rated stocks among Wall Street analysts.

When did Aura Biosciences IPO?

(AURA) raised $81 million in an initial public offering on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share.

What is Aura Biosciences' stock symbol?

Aura Biosciences trades on the NASDAQ under the ticker symbol "AURA."

When does Aura Biosciences' quiet period expire?

Aura Biosciences' quiet period expires on Wednesday, December 8th. Aura Biosciences had issued 5,400,000 shares in its initial public offering on October 29th. The total size of the offering was $75,600,000 based on an initial share price of $14.00. During Aura Biosciences' quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Aura Biosciences?

Shares of AURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aura Biosciences' stock price today?

One share of AURA stock can currently be purchased for approximately $17.75.

How much money does Aura Biosciences make?

Aura Biosciences has a market capitalization of $518.48 million.

What is Aura Biosciences' official website?

The official website for Aura Biosciences is www.aurabiosciences.com.

How can I contact Aura Biosciences?

The company can be reached via phone at 617-500-8864 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.